Vapendavir is a capsid-binding antiviral agent.1,2 It binds to a pocket in the human rhinovirus (HRV) strain HRV2 VP1 capsid protein and inhibits the cytopathic effects of HRV2 and HRV14 in HeLa Ohio cells (EC50s = 1 and 5 ng/ml, respectively), as well as in a panel of 39 HRV clinical isolates (median EC50 = 7.3 ng/ml).1 Vapendavir inhibits replication in a panel of 21 enterovirus 71 (EV71) isolates with an average EC50 value of 0.7 μM.2
1.Feil, S.C., Hamilton, S., Krippner, G.Y., et al.An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirusACS Med. Chem. Lett.3(4)303-307(2012) 2.Tijsma, A., Franco, D., Tucker, S., et al.The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replicationAntimicrob. Agents Chemother.58(11)6990-6992(2014)